ascopubs.org

Outcome with total therapy 3 (TT3) compared to total therapy 2 (TT2): Role of GEP70-defined high-risk disease with trisomy of 1q21 and activation of the proteasome gene PSMD4.

Comparison of bortezomib- and lenalidomide-based therapies for the treatment of primary (AL) amyloidosis. Background: A GEP-based risk model (GEP70) defines 15% of newly diagnosed MM with a median ...
ascopubs.org

Genomic evolution in total therapy 2 (TT2) and total therapy 3 (TT3) for newly diagnosed multiple myeloma (MM): Comparison of baseline (BL) and relapse (REL) gene expression ...

Cure fractions (CF) modeled from event-free survival and complete response duration plots in total therapy (TT) trials for newly diagnosed multiple myeloma (MM). Background: Little is known about the ...
Nature

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma

The introduction of bortezomib has greatly improved survival outcomes in MM, both in transplant and non-transplant settings. When bortezomib, not requiring adjustment for renal function, was added to ...